Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae–Producing KPC-31, a D179Y Variant of KPC-3 | Zendy

Giusy Tiseo | Zendy; Marco Falcone | Zendy; Alessandro Leonildi | Zendy; Cesira Giordano | Zendy; Simona Barnini | Zendy; Gabriele Arcari | Zendy; Alessandra Carattoli | Zendy; Francesco Menichetti | Zendy

Open Access

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae–Producing KPC-31, a D179Y Variant of KPC-3

Author(s) -

Giusy Tiseo,

Marco Falcone,

Alessandro Leonildi,

Cesira Giordano,

Simona Barnini,

Gabriele Arcari,

Alessandra Carattoli,

Francesco Menichetti

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab141

Subject(s) - ceftazidime/avibactam , klebsiella pneumoniae , meropenem , medicine , avibactam , ceftazidime , microbiology and biotechnology , bacteremia , salvage therapy , pseudomonas aeruginosa , antibiotics , antibiotic resistance , biology , chemotherapy , escherichia coli , bacteria , gene , genetics

A 68-year-old man had recurrent bacteremia by Klebsiella pneumoniae carbapenemase (KPC)–producing K. pneumoniae resistant to ceftazidime-avibactam and cefiderocol. The sequencing of a target region showed that it harbored a KPC-3 variant enzyme (D179Y; KPC-31), which confers resistance to ceftazidime-avibactam and restores meropenem susceptibility. The patient was successfully treated with meropenem-vaborbactam.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research